Publikationen der KollegiatInnen

2025

• Gairing SJ, Mildenberger, P, Gile J.... Schmidtmann I, Foerster F. Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab. JHEP Rep. 2025 Mar;7(3): 1-13 doi.org/10.1016/j.jhepr.2024.101295.

• Lederer AK, Görrissen N, Nguyen TT, Kreutz C, Rasel H, Bartsch F, Lang H, Endres K. Exploring the effects of gut microbiota on cholangiocarcinoma progression by patient-derived organoids. J Transl Med. 2025 Jan 9;23(1):34. doi: 10.1186/s12967-024-06012-x. PMID: 39789543; PMCID: PMC11716211.

2024

• Kremer WM, Schwarz A, Schepers M, Labenz C, Hahn F, Sivanathan V, Düber C, Galle PR, Sprinzl MF. Evaluation of Sonographic Muscle Measurement Using Established Muscle Markers. J Ultrasound Med. 2024 Dec;43(12):2385-2397. doi: 10.1002/jum.16574. Epub 2024 Sep 11. PMID: 39258324.

• Surov A, Wienke A, Borggrefe J, Auer TA, Gebauer B, Mähringer-Kunz A, Nensa F, Haubold J, Schaarschmidt BM, Hosch R, Kleesiek J, Diallo TD, Roehlen N, Bettinger D, Eisenblätter M, Steinle V, Mayer P, Zopfs D, Pinto Dos Santos D, Müller L, Kloeckner R. Albumin-muscle density score predicts overall survival in patients with hepatocellular cancer undergoing treatment with transarterial chemoembolization. J Cancer Res Clin Oncol. 2024 Nov 30;150(12):515. doi: 10.1007/s00432-024-06043-3. PMID: 39614916; PMCID: PMC11608168.
   
• Lederer AK, Endres K. The upper airway microbiota: how host and environment shape this ecological niche. Signal Transduct Target Ther. 2024 Oct 9;9(1):279. doi: 10.1038/s41392-024-01996-w. PMID: 39379351; PMCID: PMC11461823.
   
• Müller L, Bender D, Gairing SJ, Foerster F, Weinmann A, Mittler J, Stoehr F, Halfmann MC, Mähringer-Kunz A, Galle PR, Kloeckner R, Hahn F. Amount of ascites impacts survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization advocating for volumetric assessment. Sci Rep. 2024 Jul 17;14(1):16550. doi: 10.1038/s41598-024-67312-2. PMID: 39019953; PMCID: PMC11255265.
   
• Müller L. AI-based body composition measures in abdominal CT scans: prime time for clinical implementation? Eur Radiol. 2025 Jan;35(1):517-519. doi: 10.1007/s00330-024-10936-9. Epub 2024 Jul 12. PMID: 38995386; PMCID: PMC11632002.
   
• Müller L, Mähringer-Kunz A, Auer TA, Fehrenbach U, Gebauer B, Haubold J, Schaarschmidt BM, Kim MS, Hosch R, Nensa F, Kleesiek J, Diallo TD, Eisenblätter M, Kuzior H, Roehlen N, Bettinger D, Steinle V, Mayer P, Zopfs D, Pinto Dos Santos D, Kloeckner R. AI-derived body composition parameters as prognostic factors in patients with HCC undergoing TACE in a multicenter study. JHEP Rep. 2024 May 25;6(8):101125. doi: 10.1016/j.jhepr.2024.101125. PMID: 39139458; PMCID: PMC11321290.
   
• Gairing SJ, Mangini C, Zarantonello L, Jonasson E, Danneberg S, Sultanik P, Galle PR, Gioia S, Labenz J, Lok AS, Marquardt JU, Lauridsen MM, Bloom PP, Thabut D, Nardelli S, Montagnese S, Labenz C. PHES scores have limited impact on the risk of overt HE in patients with minimal HE. Hepatol Commun. 2024 May 3;8(5):e0438. doi: 10.1097/HC9.0000000000000438. PMID: 38701395; PMCID: PMC11073767.
   
• Gerber TS, Ridder DA, Goeppert B, Brobeil A, Stenzel P, Zimmer S, Jäkel J, Metzig MO, Schwab R, Martin SZ, Kiss A, Bergmann F, Schirmacher P, Galle PR, Lang H, Roth W, Straub BK. N-cadherin: A diagnostic marker to help discriminate primary liver carcinomas from extrahepatic carcinomas. Int J Cancer. 2024 May 15;154(10):1857-1868. doi: 10.1002/ijc.34836. Epub 2024 Jan 11. PMID: 38212892.
   
• Gairing SJ, Mangini C, Zarantonello L, Jonasson E, Dobbermann H, Sultanik P, Galle PR, Labenz J, Thabut D, Marquardt JU, Bloom PP, Lauridsen MM, Montagnese S, Labenz C. Proton pump inhibitor use and risk of hepatic encephalopathy: A multicentre study. JHEP Rep. 2024 Apr 26;6(8):101104. doi: 10.1016/j.jhepr.2024.101104. PMID: 39035069; PMCID: PMC11260370.
   
• Ben Khaled N, Möller M, Jochheim LS, Leyh C, Ehmer U, Böttcher K, Pinter M, Balcar L, Scheiner B, Weich A, Leicht HB, Zarka V, Ye L, Schneider J, Piseddu I, Öcal O, Rau M, Sinner F, Venerito M, Gairing SJ, Förster F, Mayerle J, De Toni EN, Geier A, Reiter FP. Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events. JHEP Rep. 2024 Apr 8;6(6):101065. doi: 10.1016/j.jhepr.2024.101065. PMID: 38798717; PMCID: PMC11126929.
   
• Schleicher EM, Gairing SJ, Castven D, Hock CS, Dobbermann H, Heinrich S, Meineck M, Kaps L, Galle PR, Weinmann-Menke J, Nguyen-Tat M, Marquardt JU, Labenz C. Lower uromodulin serum levels are associated with poorer prognosis in patients with cirrhosis and hepatorenal syndrome type 2. Am J Physiol Gastrointest Liver Physiol. 2024 May 1;326(5):G583-G590. doi: 10.1152/ajpgi.00304.2023. Epub 2024 Mar 19. PMID: 38502914.
   
• Auer TA, Müller L, Schulze D, Anhamm M, Bettinger D, Steinle V, Haubold J, Zopfs D, Pinto Dos Santos D, Eisenblätter M, Gebauer B, Kloeckner R, Collettini F. CT-guided High-Dose-Rate Brachytherapy versus Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma. Radiology. 2024 Feb;310(2):e232044. doi: 10.1148/radiol.232044. PMID: 38319166.
   
• Michel M, Doll M, Albert N, Morgenstern M, Behr A, Maxeiner S, Labenz C, Galle PR, Schattenberg JM. Obesity and harmful alcohol consumption are predictors for advanced liver disease in the disease management program for type 2 diabetes. United European Gastroenterol J. 2024 Jan 11. doi:10.1002/ueg2.12511. Epub ahead of print. PMID: 38206118.

• Gerber TS, Strobl S, Marx A, Roth W, Porubsky S. Epidemiology of thymomas and thymic carcinomas in the United States and Germany, 1999-2019. Front Oncol. 2024 Jan 9;13:1308989. doi: 10.3389/fonc.2023.1308989. PMID: 38264756; PMCID: PMC10805269.

• Michel M, Schattenberg JM. Editorial: Does knowledge about liver disease enhance adherence to lifestyle recommendations? Aliment Pharmacol Ther. 2024 Jan;59(2):283-284. doi: 10.1111/apt.17789. PMID: 38153277

2023

• Armandi A, Michel M, Gjini K, Emrich T, Bugianesi E, Schattenberg JM. Emerging concepts in the detection of liver fibrosis in non-alcoholic fatty liver disease. Expert Rev Mol Diagn. 2023 Jul-Dec;23(9):771-782. doi: 10.1080/14737159.2023.2242779. Epub 2023 Aug 1. PMID: 37505901.

• Schleicher EM, Kaps L, Schattenberg JM, Galle PR, Wörns MA, Gairing SJ, Labenz C. Higher scores in the Clinical Frailty Scale are associated with covert and overt hepatic encephalopathy in patients with cirrhosis. Dig Liver Dis. 2023 Dec 16:S1590-8658(23)01081-2. doi: 10.1016/j.dld.2023.12.001. Epub ahead of print. PMID: 38105147.

• Armandi A, Merizian T, Werner MM, Coxson HO, Sanavia T, Birolo G, Gashaw I, Ertle J, Michel M, Galle PR, Labenz C, Emrich T, Schattenberg JM. Variability of transient elastography-based spleen stiffness performed at 100 Hz. Eur Radiol Exp. 2023 Dec 12;7(1):79. doi: 10.1186/s41747-023-00393-2. PMID: 38087079; PMCID: PMC10716091. 

• Michel M, Schattenberg JM. Uncouplers of mitochondrial oxidation in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2023 Dec;8(12):1060-1061. doi: 10.1016/S2468-1253(23)00241-8. Epub 2023 Oct 5. PMID: 37806315.

• Gairing SJ, Mangini C, Zarantonello L, Gioia S, Nielsen EJ, Danneberg S, Gabriel M, Ehrenbauer AF, Bloom PP, Ripoll C, Sultanik P, Galle PR, Labenz J, Thabut D, Zipprich A, Lok AS, Weissenborn K, Marquardt JU, Lauridsen MM, Nardelli S, Montagnese S, Labenz C. Prevalence of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Multicenter Study. Am J Gastroenterol. 2023 Dec 1;118(12):2191-2200. doi: 10.14309/ajg.0000000000002251. Epub 2023 Mar 20. PMID: 36940426.
   
• Kaps L, Medina-Montano C, Bros M, Grabbe S, Gairing SJ, Schleicher EM, Gehring S, Schattenberg JM, Galle PR, Wörns MA, Nagel M, Labenz C. Comparison of Inflammatory Cytokine Levels in Hepatic and Jugular Veins of Patients with Cirrhosis. Mediators Inflamm. 2023 Nov 29;2023:9930902. doi: 10.1155/2023/9930902. PMID: 38077228; PMCID: PMC10700970

• Gerber TS, Porubsky S. Benign lesions of the mediastinum. Histopathology. 2024 Jan;84(1):183-195.doi: 10.1111/his.15088. Epub 2023 Nov 21. PMID: 37988262.

• Gairing SJ, Mangini C, Zarantonello L, Gioia S, Nielsen EJ, Danneberg S, Lok AS, Sultanik P, Galle PR, Labenz J, Thabut D, Marquardt JU, Bloom PP, Lauridsen MM, Montagnese S, Nardelli S, Labenz C. Minimal hepatic encephalopathy is associated with a higher risk of overt hepatic encephalopathy and poorer survival. J Intern Med. 2023 Nov 20. doi: 10.1111/joim.13747. Epub ahead of print. PMID: 37983845.

• Stortz M, Shmanko K, Kraus D, Gairing S, Boedecker-Lips S, Förster F, Weinmann A, Weinmann-Menke J. Plasma exchange for treatment of a therapy-related thrombotic microangiopathy in a patient with advanced hepatocellular carcinoma-A case report. Clin Case Rep. 2023 Nov 9;11(11):e8124. doi: 10.1002/ccr3.8124. PMID: 37953891; PMCID: PMC10636558.

• Wirth M, Ruckes C, Michel M, Schattenberg JM. Development and validation of a multivariable risk prediction model for hepatic steatosis in patients with HIV infection. AIDS. 2023 Nov 6. doi: 10.1097/QAD.0000000000003779. Epub ahead of print. PMID: 37924505.

• Albrecht T, Rossberg A, Albrecht JD, Nicolay JP, Straub BK, Gerber TS, Albrecht M, Brinkmann F, Charbel A, Schwab C, Schreck J, Brobeil A, Flechtenmacher C, von Winterfeld M, Köhler BC, Springfeld C, Mehrabi A, Singer S, Vogel MN, Neumann O, Stenzinger A, Schirmacher P, Weis CA, Roessler S, Kather JN, Goeppert B. Deep Learning-Enabled Diagnosis of Liver Adenocarcinoma. Gastroenterology. 2023 Nov;165(5):1262-1275. doi: 10.1053/j.gastro.2023.07.026. Epub 2023 Aug 9. PMID: 37562657.

• Gairing SJ, Schleicher EM, Kaps L, Schulte-Beerbuehl S, Steiner K, Labenz J, Schattenberg JM, Galle PR, Wörns MA, Labenz C. Development and evaluation of a virtual reality driving test for patients with cirrhosis. Hepatol Commun. 2023 Oct 31;7(11):e0303. doi: 10.1097/HC9.0000000000000303. PMID: 37902506; PMCID: PMC10617881.

• Schleicher, E., Labenz, C. Lactulose zur Behandlung von schlechter Lebensqualität bei Leberzirrhose. Gastro-News 2023 Oct 16;10 (5). doi.org/10.1007/s15036-023-3305-0

• Roehlen N, Stoehr F, Müller L, Luxenburger H, Gairing SJ, Reincke M, Schultheiss M, Berisha F, Weinmann A, Foerster F, Marquardt JU, Thimme R, Galle PR, Bettinger D, Kloeckner R. Prediction of postembolization syndrome after transarterial chemoembolization of hepatocellular carcinoma and its impact on prognosis. Hepatol Commun. 2023 Sep 27;7(10):e0252. doi:10.1097/HC9.0000000000000252. PMID: 37756031; PMCID: PMC10531352.

• Lederer AK, Rasel H, Kohnert E, Kreutz C, Huber R, Badr MT, Dellweg PKE, Bartsch F, Lang H. Gut Microbiota in Diagnosis, Therapy and Prognosis of Cholangiocarcinoma and Gallbladder Carcinoma-A Scoping Review. Microorganisms. 2023 Sep 21;11(9):2363. doi: 10.3390/microorganisms11092363. PMID: 37764207; PMCID: PMC10538110.

• Duwe G, Müller L, Ruckes C, Fischer ND, Frey LJ, Börner JH, Rölz N, Haack M, Sparwasser P, Jorg T, Neumann CCM, Tsaur I, Höfner T, Haferkamp A, Hahn F, Mager R, Brandt MP. Change in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma-Evaluation of a Novel Approach of Fully Automated Artificial Intelligence Based Splenic Segmentation. Biomedicines. 2023 Sep 7;11(9):2482. doi: 10.3390/biomedicines11092482. PMID: 37760923; PMCID: PMC10526098.

• Gairing SJ, Schleicher EM, Labenz C. Diabetes mellitus - risk factor and potential future target for hepatic encephalopathy in patients with liver cirrhosis? Metab Brain Dis. 2023 Jun;38(5):1691-1700. doi: 10.1007/s11011-022-01068-4. Epub 2022 Aug 24. PMID: 36001211; PMCID: PMC10185646.

• Michel M, Labenz C, Armandi A, Kaps L, Kremer WM, Galle PR, Grimm D, Sprinzl M, Schattenberg JM. Metabolic dysfunction-associated fatty liver disease in people living with HIV. Sci Rep. 2023 Jun 6;13(1):9158. doi: 10.1038/s41598-023-32965-y. PMID: 37280241; PMCID: PMC10244325.

• Graafen D, Stoehr F, Halfmann MC, Emrich T, Foerster F, Yang Y, Düber C, Müller L*, Kloeckner R*. Quantum iterative reconstruction on a photon-counting detector CT improves the quality of hepatocellular carcinoma imaging. Cancer Imaging. 2023 Jul 21;23(1):69. doi: 10.1186/s40644-023-00592-5. PMID: 37480062; PMCID: PMC10362630. *Shared senior authorship.

• Müller L, Gairing SJ, Foerster F, Weinmann A, Mittler J, Stoehr F, Graafen D, Düber C, Galle PR, Kloeckner R, Hahn F. Portal hypertension in patients with hepatocellular carcinoma and immunotherapy: prognostic relevance of CT-morphologic estimates. Cancer Imaging. 2023 Apr 25;23(1):40. doi: 10.1186/s40644-023-00558-7. PMID: 37098584; PMCID: PMC10127076.

• Schleicher, E., Labenz, C. Prognoseeinschätzung durch Patienten und Hepatologen Gastro-News 2023 Apr 17; 10 (2). doi.org/10.1007/s15036-023-3187-1

• Gairing SJ, Schleicher EM, Galle PR, Labenz C. Prediction and prevention of the first episode of overt hepatic encephalopathy in patients with cirrhosis. Hepatol Commun. 2023 Mar 17;7(4):e0096. doi: 10.1097/HC9.0000000000000096. PMID: 36930868; PMCID: PMC10027066.

• Michel M, Wahl A, Anders M, Alqahtani SA, Kremer WM, Galle PR, Labenz C, Grimm D, Sprinzl M, Schattenberg JM. Significant liver fibrosis is a predictor of poor health-related quality of life in people living with HIV. Qual Life Res. 2023 Feb;32(2):401-411. doi: 10.1007/s11136-022-03232-w. Epub 2022 Aug 22. PubMed PMID: 35996039; PubMed Central PMCID: PMC9911489

• Gerber TS, Witzel HR, Weinmann A, Bartsch F, Schindeldecker M, Galle PR, Lang H, Roth W, Ridder DA, Straub BK. Reduced Lipid Peroxidation Predicts Unfavorable Prognosis in Hepatocellular Carcinoma, but Not Intrahepatic Cholangiocarcinoma. Biomedicines. 2023;11(9):2471.

• Foersch S, Glasner C, Woerl AC, Eckstein M, Wagner DC, Schulz S, Kellers F, Fernandez A, Tserea K, Kloth M, Hartmann A, Heintz A, Weichert W, Roth W, Geppert C, Kather JN, Jesinghaus M. Multistain deep learning for prediction of prognosis and therapy response in colorectal cancer. Nat Med. 2023 Jan 9. doi: 10.1038/s41591-022-02134-1. Epub ahead of print. PMID: 36624314.
   
• Gairing SJ, Kaps L, Schleicher EM, Galle PR, Labenz C. Ammonia - an old friend with a new area of application. J Hepatol. 2023 Jan;78(1):e22-e23. doi: 10.1016/j.jhep.2022.08.007. Epub 2022 Aug 19. PMID: 35988683.

• Penzkofer L, Gröger LK, Hoppe-Lotichius M, Baumgart J, Heinrich S, Mittler J, Gerber TS, Straub BK, Weinmann A, Bartsch F, Lang H. Mixed Hepatocellular Cholangiocarcinoma: A Comparison of Survival between Mixed Tumors, Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma from a Single Center. Cancers (Basel). 2023 Jan 19;15(3):639. doi: 10.3390/cancers15030639. PMID: 36765596; PMCID: PMC9913586.

• Gairing SJ, Danneberg S, Kaps L, Nagel M, Schleicher EM, Quack C, Engel S, Bittner S, Galle PR, Schattenberg JM, Wörns MA, Luessi F, Marquardt JU, Labenz C. Elevated serum levels of glial fibrillary acidic protein are associated with covert hepatic encephalopathy in patients with cirrhosis. JJHEP Rep. 2023 Jan 18;5(4):100671. doi: 10.1016/j.jhepr.2023.100671. PMID: 36866390; PMCID: PMC9972561.

• Galle PR, Schleicher EM, Labenz C; Physiologie der Leber und Gallenwege; Viszeral- und Allgemeinchirurgie; Hrsg. Martin Kreis, Detlef K. Bartsch und Hauke Lang, Springer Verlag 2023 (Buchbeitrag)

2022

• Gerber TS, Straub BK. IgG4-assoziierte Cholangitis. Pathologie. 2022 Dec 12. German. doi: 10.1007/s00292-022-01169-y. Epub ahead of print. PMID: 36508049.
   
• Kaps L, Omogbehin L, Hildebrand K, Gairing SJ, Schleicher EM, Moehler M, Rahman F, Schattenberg JM, Wörns MA, Galle PR, Labenz C. Health literacy in gastrointestinal diseases: a comparative analysis between patients with liver cirrhosis, inflammatory bowel disease and gastrointestinal cancer. Sci Rep. 2022 Dec 6;12(1):21072. doi: 10.1038/s41598-022-25699-w. PMID: 36473962; PMCID: PMC9726701.
   
• Schleicher EM, Gairing SJ, Galle PR, Weinmann-Menke J, Schattenberg JM, Kostev K, Labenz C. A higher FIB-4 index is associated with an increased incidence of renal failure in the general population. Hepatol Commun. 2022 Dec;6(12):3505-3514. doi: 10.1002/hep4.2104. Epub 2022 Oct 4. PMID: 36194174; PMCID: PMC9701474.
   
• Gairing SJ, Schleicher EM, Müller L, Labenz C, Darstein F, Grimm D, Sivanathan V, Weinmann A, Wörns MA, Kloeckner R, Pitton MB, Thieringer F, Rahman KF, Galle PR, Schattenberg JM, Foerster F. Bevacizumab in combination with octreotide rescues a patient with liver cirrhosis, GAVE syndrome and refractory hemorrhage - a case report. Z Gastroenterol. 2022 Nov 15. English. doi: 10.1055/a-1959-2660. Epub ahead of print. PMID: 36379462.
   
• Schaarschmidt BM, Kloeckner R, Dertnig T, Demircioglu A, Müller L, Auer TA, Pinto Dos Santos D, Steinle V, Miederer M, Gebauer B, Radunz S, Kasper S, Weber M, Theysohn J. Real-life experience in the treatment of intrahepatic cholangiocarcinoma by 90Y radioembolization: A multicenter retrospective study. J Nucl Med. 2022 November 3. doi: 10.2967/jnumed.122.264598. Epub ahead of print. PMID: 36328487.

• Stoehr F, Kloeckner R, Pinto dos Santos D, Schnier M, Müller L, Mähringer-Kunz A, Dratsch T, Schotten S, Weinmann A, Galle PR, Mittler J, Düber C, Hahn F. Radiomics-Based Prediction of Future Portal Vein Tumor Infiltration in Patients with HCC—A Proof-of-Concept Study. Cancers. 2022; 14(24):6036. doi: 10.3390/cancers14246036. PMID: 36551521; PMCID: PMC9775514.

• Scheiner B, Roessler D, Phen S, Lim M, Pomej K, Pressiani T, Cammarota A, Fründt TW, von Felden J, Schulze K, Himmelsbach V, Finkelmeier F, Deibel A, Siebenhüner AR, Shmanko K, Radu P, Schwacha-Eipper B, Ebert MP, Teufel A, Djanani A, Hucke F, Balcar L, Philipp AB, Hsiehchen D, Venerito M, Sinner F, Trauner M, D'Alessio A, Fulgenzi CAM, Pinato DJ, Peck-Radosavljevic M, Dufour JF, Weinmann A, Kremer AE, Singal AG, De Toni EN, Rimassa L, Pinter M. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma. JHEP Rep. 2022 Oct 27;5(1):100620. doi: 10.1016/j.jhepr.2022.100620. PMID: 36578451; PMCID: PMC9791167.
   
• Gairing SJ, Kuchen R, Müller L, Cankaya A, Weerts J, Kapucu A, Sachse S, Zimpel C, Stoehr F, Pitton MB, Mittler J, Straub BK, Marquardt JU, Schattenberg JM, Labenz C, Kloeckner R, Weinmann A, Galle PR, Wörns MA, Foerster F. 13 C-Methacetin Breath Test Predicts Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Clin Transl Gastroenterol. 2022 Oct 1. doi: 10.14309/ctg.0000000000000529. PMID: 36087052; PMCID: PMC9624494.
   
• Baumgart J, Bartsch F, Kloth M, Klöckner R, Lang H. Role of associating liver partition and portal vein ligation for staged hepatectomy for advanced colorectal liver disease: indispensable or overstressed? Minerva Surg. 2022 Oct;77(5):421-427. doi: 10.23736/S2724-5691.22.09544-2. Epub 2022 Sep 9. PMID: 36083114.
   
• Karl M, Hasselwander S, Zhou Y, Reifenberg G, Kim YO, Park K-S, Ridder DA, Wang X, Seidel E, Hövelmeyer N, Straub BK, Li H, Schuppan D, Xia N. Dual roles of B lymphocytes in mouse models of diet-induced nonalcoholic fatty liver disease. Hepatology. 2022 Oct;76(4):1135-1149. doi: 10.1002/hep.32428. Epub 2022 Mar 17. PMID: 35218234.

• Kremer WM, Gairing SJ, Kaps L, Ismail E, Kalampoka V, Hilscher M, Michel M, Siegel E, Schattenberg JM, Galle PR, Sprinzl MF, Wörns MA, Nagel M, Labenz C. Characteristics of bacterial infections and prevalence of multidrug-resistant bacteria in hospitalized patients with liver cirrhosis in Germany. Ann Hepatol. 2022 Sep-Oct;27(5):100719. doi: 10.1016/j.aohep.2022.100719. Epub 2022 Apr 20. PMID: 35460883.

• Michel M, Labenz C, Wahl A, Anders M, Armandi A, Huber Y, Galle PR, Sprinzl M, Schattenberg JM. Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV. AIDS. 2022 Oct 1;36(12):1665-1674. doi: 10.1097/QAD.0000000000003312. Epub 2022 Jul 8. PMID: 35849074; PMCID: PMC9451864.

• Penzkofer L, Mittler J, Heinrich S, Wachter N, Straub BK, Kloeckner R, Stoehr F, Gairing SJ, Bartsch F, Lang H. Outcome after Resection for Hepatocellular Carcinoma in Noncirrhotic Liver—A Single Centre Study J Clin Med. 2022 Sep 30;11(19):5802. doi: 10.3390/jcm11195802. PMID: 36233670; PMCID: PMC9570688.

• Müller L, Gairing SJ, Kloeckner R, Foerster F, Schleicher EM, Weinmann A, Mittler J, Stoehr F, Halfmann MC, Düber C, Galle PR, Hahn F. The prognostic role of early tumor shrinkage in patients with hepatocellular carcinoma undergoing immunotherapy. Cancer Imaging. 2022 Sep 24. doi: 10.1186/s40644-022-00487-x. PMID: 36153569; PMCID: PMC9509639.
   
• Gairing SJ, Schleicher EM, Labenz C. Diabetes mellitus - risk factor and potential future target for hepatic encephalopathy in patients with liver cirrhosis? Metab Brain Dis. 2022 Aug 24. doi: 10.1007/s11011-022-01068-4. Epub ahead of print. PMID: 36001211.
   
• Michel M, Wahl A, Anders M, Alqahtani SA, Kremer WM, Galle PR, Labenz C, Grimm D, Sprinzl M, Schattenberg JM. Significant liver fibrosis is a predictor of poor health-related quality of life in people living with HIV. Qual Life Res. 2022 Aug 22. doi: 10.1007/s11136-022-03232-w. Epub ahead of print. PMID: 35996039.
   
• Müller L, Mähringer-Kunz A, Auer TA, Fehrenbach U, Gebauer B, Haubold J, Theysohn JM, Kim MS, Kleesiek J, Diallo TD, Eisenblätter M, Bettinger D, Steinle V, Mayer P, Zopfs D, Pinto Dos Santos D, Kloeckner R. Low bone mineral density is a prognostic factor for elderly patients with HCC undergoing TACE: results from a multicenter study. Eur Radiol. 2022 Aug 20. doi: 10.1007/s00330-022-09069-8. Epub ahead of print. PMID: 35986768.
   
• Gerber TS, Ridder DA, Schindeldecker M, Weinmann A, Duret D, Breuhahn K, Galle PR, Schirmacher P, Roth W, Lang H, Straub BK. Constitutive Occurrence of E:N-cadherin Heterodimers in Adherens Junctions of Hepatocytes and Derived Tumors Cells 2022 Aug 12;11(16):2507.doi: 10.3390/cells11162507. PMID: 36010583; PMCID: PMC9406782. 
   
• Michel M, Labenz C, Anders M, Wahl A, Girolstein L, Kaps L, Kremer WM, Huber Y, Galle PR, Sprinzl M, Schattenberg JM. Effect of hepatic steatosis and associated metabolic comorbidities on health-related quality of life in people living with HIV. Hepatology Communications. 2022 Aug;6(8):2011-2021. doi: 10.1002/hep4.1958. Epub 2022 Apr 12. PMID: 35411570; PMCID: PMC9315116.

• Müller L, Gairing SJ, Kloeckner R, Foerster F, Weinmann A, Mittler J, Stoehr F, Emrich T, Düber C, Galle PR, Hahn F. Baseline Splenic Volume Outweighs Immuno-Modulated Size Changes with Regard to Survival Outcome in Patients with Hepatocellular Carcinoma under Immunotherapy. Cancers (Basel). 2022 Jul 22;14(15):3574. doi: 10.3390/cancers14153574. PMID: 35892833; PMCID: PMC9332404.
   
• Gairing SJ, Müller L, Penzkofer L, Stoehr F, Michel M, Shmanko K, Galle PR. Diagnostik und Therapie des primären Leberzellkarzinoms. Gastroenterologie 2022 July 21;17:403-412. doi:10.1007/s11377-022-00636-5

• Michel M, Labenz C, Wahl A, Anders M, Armandi A, Huber Y, Galle P, Sprinzl M, Schattenberg JM. Prevalence and risk factors of non-alcoholic steatohepatitis with significant fibrosis in people living with HIV. AIDS, July 2022, doi: 10.1097/QAD.0000000000003312.

• Schleicher EM, Kremer WM, Kalampoka V, Gairing SJ, Kaps L, Schattenberg JM, Galle PR, Wörns MA, Nagel M, Weinmann-Menke J, Labenz C. Frailty as Tested by the Clinical Frailty Scale Is a Risk Factor for Hepatorenal Syndrome in Patients With Liver Cirrhosis. Clin Transl Gastroenterol. 2022 Jul 1;13(7):e00512. doi: 10.14309/ctg.0000000000000512. Epub 2022 Jun 13. PMID: 35905416.

• Gerber TS, Müller L, Bartsch F, Gröger LK, Schindeldecker M, Ridder DA, Goeppert B, Möhler M, Dueber C, Lang H, Roth W, Kloeckner R, Straub BK. Integrative Analysis of Intrahepatic Cholangiocarcinoma Subtypes for Improved Patient Stratification: Clinical, Pathological, and Radiological Considerations. Cancers (Basel), 2022 June 28;14(13):3156.doi: 10.3390/cancers14133156. PMID: 35804931; PMCID: PMC9264781.
   
• Gairing SJ, Schattenberg JM. The unmet need of personalized HCC screening-Lessons learned from the Swedish nationwide registries. United European Gastroenterol J. 2022 Jun;10(5):447-448. doi: 10.1002/ueg2.12239. Epub 2022 May 14. PMID: 35567573; PMCID: PMC9189471.
   
• Gerber TS, Goeppert B, Hausen A, Witzel HR, Bartsch F, Schindeldecker M, Gröger LK, Ridder DA, Cahyadi O, Esposito I, Gaida MM, Schirmacher P, Galle PR, Lang H, Roth W, Straub BK. N-Cadherin Distinguishes Intrahepatic Cholangiocarcinoma from Liver Metastases of Ductal Adenocarcinoma of the Pancreas. Cancers (Basel) 2022 Jun 23;14(13):3091. doi: 10.3390/cancers14133091. PMID: 35804866; PMCID: PMC9264797.
   
• Foerster F, Gairing SJ, Ilyas SI, Galle PR. Emerging immunotherapy for HCC: A guide for hepatologists. (Review) Hepatology. 2022 Jun;75(6):1604-1626. doi: 10.1002/hep.32447. PMID: 35253934; PMCID: PMC9117522.

• Hatzidakis A, Müller L, Krokidis M, Kloeckner R. Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. Cancers. 2022 May 17. doi: 10.3390/cancers14102469. PMID: 35626073; PMCID: PMC9139740.
   
• Kaps L, Schleicher EM, Medina Montano C, Bros M, Gairing SJ, Ahlbrand CJ, Michel M, Klimpke P, Kremer WM, Holtz S, Boedecker-Lips SC, Galle PR, Kraus D, Schattenberg JM, Labenz C, Weinmann-Menke J. Influence of Advanced Organ Support (ADVOS) on Cytokine Levels in Patients with Acute-on-Chronic Liver Failure (ACLF). J Clin Med. 2022 May 15;11(10):2782. doi: 10.3390/jcm11102782. PMID: 35628913; PMCID: PMC9144177.
   
• Jungmann F, Müller L, Hahn F, Weustenfeld M, Dapper AK, Mähringer-Kunz A, Graafen D, Düber C, Schafigh D, Pinto Dos Santos D, Mildenberger P, Kloeckner R. Commercial AI solutions in detecting COVID-19 pneumonia in chest CT: not yet ready for clinical implementation? Eur Radiol. 2022 May;32(5):3152-3160. doi: 10.1007/s00330-021-08409-4. Epub 2021 Dec 23. PMID: 34950973; PMCID: PMC8700707.
   
• Gairing SJ, Müller L, Kloeckner R, Galle PR, Labenz C. Review article: post-TIPSS hepatic encephalopathy—current knowledge and future perspectives. Aliment Pharmacol Ther. 2022 May;55(10):1265-1276. doi: 10.1111/apt.16825. Epub 2022 Feb 18. PMID: 35181894.
   
• Gairing SJ, Anders J, Kaps L, Nagel M, Michel M, Kremer WM, Hilscher M, Galle PR, Schattenberg JM, Wörns MA, Labenz C. Evaluation of IL-6 for Stepwise Diagnosis of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis. Hepatol Commun. 2022 May;6(5):1113-1122. doi: 10.1002/hep4.1883. Epub 2022 Jan 14. PMID: 35032100; PMCID: PMC9035565.
   
• Kaps L, Lukac L, Michel M, Kremer WM, Hilscher M, Gairing SJ, Galle PR, Schattenberg JM, Wörns MA, Nagel M, Labenz C. Liver Frailty Index for Prediction of Short-Term Rehospitalization in Patients with Liver Cirrhosis. Diagnostics (Basel). 2022 Apr 24;12(5):1069. doi: 10.3390/diagnostics12051069. PMID: 35626226; PMCID: PMC9139749.
   
• Gairing SJ, Galle PR, Schattenberg JM, Kostev K, Labenz C. Portal vein thrombosis is associated with an increased risk of bone fractures. PLoS One. 2022 Apr 22;17(4):e0267535. doi: 10.1371/journal.pone.0267535. PMID: 35452487; PMCID: PMC9032344.
   
• Müller L, Kloeckner R, Mähringer-Kunz A, Stoehr F, Düber C, Arnhold G, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto dos Santos D, Hahn F. Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC. European Radiology, April 2022, doi: 10.1007/s00330-022-08737-z. Epub 2022 Apr 8. PMID: 35394184; PMCID: PMC9381627.
   
• Labenz, C., Schleicher, E. Terlipressin plus Albumin zur Therapie des hepatorenalen Syndroms. Gastro-News 2022 Apr 22; 9, 24–25. doi.org/10.1007/s15036-022-2474-6
   
• Ridder DA, Weinmann A, Schindeldecker M, Urbansky LL, Berndt K, Gerber TS, Lang H, Lotz J, Lackner KJ, Roth W, Straub BK. Comprehensive clinicopathologic study of alpha fetoprotein-expression in a large cohort of patients with hepatocellular carcinoma. Int J Cancer. 2022 Mar 15;150(6):1053-1066. doi: 10.1002/ijc.33898. Epub 2021 Dec 18. PMID: 34894400.
   
• de Castro T, Jochheim LS, Bathon M, Welland S, Scheiner B, Shmanko K, Roessler D, Ben Khaled N, Jeschke M, Ludwig JM, Marquardt JU, Weinmann A, Pinter M, Lange CM, Vogel A, Saborowski A. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. Ther Adv Med Oncol. 2022 Feb 26;14:17588359221080298. doi: 10.1177/17588359221080298. PMID: 35251317; PMCID: PMC8891886.
   
• Müller L, Hahn F, Auer TA, Fehrenbach U, Gebauer B, Haubold J, Zensen S, Kim MS, Eisenblätter M, Diallo TD, Bettinger D, Steinle V, Chang DH, Zopfs D, Pinto Dos Santos D, Kloeckner R. Tumor Burden in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Head-to-Head Comparison of Current Scoring Systems. Front Oncol. 2022 Feb 23. doi: 10.3389/fonc.2022.850454. PMID: 35280804; PMCID: PMC8904349.
   
• Scheiner B, Pomej K, Kirstein MM, Hucke F, Finkelmeier F, Waidmann O, Himmelsbach V, Schulze K, von Felden J, Fründt TW, Stadler M, Heinzl H, Shmanko K, Spahn S, Radu P, Siebenhüner AR, Mertens JC, Rahbari NN, Kütting F, Waldschmidt DT, Ebert MP, Teufel A, De Dosso S, Pinato DJ, Pressiani T, Meischl T, Balcar L, Müller C, Mandorfer M, Reiberger T, Trauner M, Personeni N, Rimassa L, Bitzer M, Trojan J, Weinmann A, Wege H, Dufour JF, Peck-Radosavljevic M, Vogel A, Pinter M. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol. 2022 Feb;76(2):353-363. doi: 10.1016/j.jhep.2021.09.035. Epub 2021 Oct 12. PMID: 34648895.
   
• Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Fehrenbach U, Auer TA, Gebauer B, Kloeckner R. Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. United European Gastroenterol J. 2022 Feb;10(1):41-53. doi: 10.1002/ueg2.12188. Epub 2021 Dec 16. PMID: 34918471; PMCID: PMC8830270.
   
• Foerster F, Gairing SJ, Müller L, Galle PR. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol. 2022 Feb;76(2):446-457. doi: 10.1016/j.jhep.2021.09.007. Epub 2021 Sep 20. PMID: 34555422.
   
• Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto dos Santos D, Pitton MB, Düber C, Fehrenbach U, Auer TA, Gebauer B, Kloeckner R. Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. United European Gastroenterol J. 2022 Feb;10(1):41-53. doi: 10.1002/ueg2.12188. Epub 2021 Dec 16. PMID: 34918471; PMCID: PMC8830270.

• Ulmer B, Odenthal M, Buettner R, Roth W, Kloth M. Diffusion kernel-based predictive modeling of KRAS dependency in KRAS wild type cancer cell lines. NPJ Syst Biol Appl. 2022 Jan 19;8(1):2. doi: 10.1038/s41540-021-00211-8. PMID: 35046405; PMCID: PMC8770632.
   
• Welland S, Leyh C, Finkelmeier F, Jefremow A, Shmanko K, Gonzalez-Carmona MA, Kandulski A, Jeliazkova P, Best J, Fründt TW, Djanani A, Pangerl M, Maieron A, Greil R, Fricke C, Sookthai D, Günther R, Schmiderer A, Wege H, Venerito M, Ehmer U, Müller M, Strassburg CP, Weinmann A, Siebler J, Waidmann O, Lange CM, Saborowski A, Vogel A. Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study. Liver Cancer. 2022 Jan 14;11(3):219-232. doi: 10.1159/000521746. PMID: 35949288; PMCID: PMC9218621.
   
• Ridder DA, Urbansky LL, Witzel HR, Schindeldecker M, Weinmann A, Berndt K, Gerber TS, Köhler BC, Nichetti F, Ludt A, Gehrke N, Schattenberg JM, Heinrich S, Roth W, Straub BK. Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome. Cancers (Basel). 2022 Jan 15;14(2):430. doi: 10.3390/cancers14020430. PMID: 35053591; PMCID: PMC8774263.

• Müller L, Hahn F, Jungmann F, Mähringer-Kunz A, Stoehr F, Halfmann MC, Pinto Dos Santos D, Hinrichs J, Auer TA, Düber C, Kloeckner R. Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis? Cancer Imaging. 2022 Jan 11;22(1):5. doi: 10.1186/s40644-022-00446-6. PMID: 35016731; PMCID: PMC8753936.

2021

• Thol F, Gairing SJ, Czauderna C, Thomaidis T, Gamstätter T, Huber Y, Vollmar J, Lorenz J, Michel M, Bartsch F, Müller L, Kloeckner R, Galle PR, Wörns MA, Marquardt JU, Moehler M, Weinmann A, Foerster F. Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer. JHEP Rep. 2021 Dec 16;4(3):100417. doi: 10.1016/j.jhepr.2021.100417. PMID: 35141511; PMCID: PMC8792293.

• Gairing SJ, Galle PR, Schattenberg JM, Kostev K, Labenz C. Portal Vein Thrombosis Is Associated with an Increased Incidence of Depression and Anxiety Disorders. J Clin Med. 2021 Dec 2;10(23):5689. doi: 10.3390/jcm10235689. PMID: 34884391; PMCID: PMC8658138.
   
• Lang H, Kloth M, Moehler M, Roth W, Baumgart J. Response to the Comment on "Extended Molecular Profiling Improves Stratification and Prediction of Survival
  After Resection of Colorectal Liver Metastases". Ann Surg. 2021 Dec. 1;274(6):e714. doi: 10.1097/SLA.0000000000004097. PMID: 32649462.
   
• Michel M, Hess C, Kaps L, Kremer WM, Hilscher M, Galle PR, Moehler M, Schattenberg JM, Wörns MA, Labenz C, Nagel M. Elevated serum levels of methylglyoxal are associated with impaired liver function in patients with liver cirrhosis. Sci Rep. 2021 Oct 15;11(1):20506. doi: 10.1038/s41598-021-00119-7. PMID: 34654829; PMCID: PMC8519993.

• Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Michel M, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. Cancers (Basel). 2021 Oct 7;13(19):5018. doi: 10.3390/cancers13195018. PMID: 34638502; PMCID: PMC8508385.

• Michel M, Spinelli F, Grambihler A, Labenz C, Nagel M, Kaps L, Huber Y, Galle P, Wörns MA, Schattenberg JM. Health-related quality of life in patients with autoimmune hepatitis. Qual Life Res. 2021 Oct;30(10):2853-2861. doi: 10.1007/s11136-021-02850-0. Epub 2021 May 12. PMID: 33978892; PMCID: PMC8481193.

• Moehler M, Michel M, Stein A, Trojan J, Marquardt J, Tintelnot J, Waidmann O, Weinmann A, Woerns MA, Schroeder H, Maenz M, Foerster F. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer. Future Oncol. 2021 Sep;17(25):3309-3319. doi: 10.2217/fon-2021-0278. Epub 2021 May 17. PMID: 33993741.

• Lang H, Baumgart J, Roth W, Moehler M, Kloth M. Cancer gene related characterization of patterns and point of recurrence after resection of colorectal liver metastases. Ann Transl Med. 2021 Sep;9(17):1372. doi: 10.21037/atm-21-292. PMID: 34733924; PMCID: PMC8506541.
   
• Czauderna C, Poplawski A, O'Rourke CJ, Castven D, Pérez-Aguilar B, Becker D, Heilmann-Heimbach S, Odenthal M, Amer W, Schmiel M, Drebber U, Binder H, Ridder DA, Schindeldecker M, Straub BK, Galle PR, Andersen JB, Thorgeirsson SS, Park YN, Marquardt JU. Epigenetic modifications precede molecular alterations and drive human hepatocarcinogenesis. JCI Insight. 2021 Sep 8;6(17):e146196. doi: 10.1172/jci.insight.146196. PMID: 34375307; PMCID: PMC8492348.

• Lang H, Baumgart J, Heinrich S, Huber T, Heuft LK, Margies R, Mittler J, Hahn F, Gerber TS, Foerster F, Weinmann A, Marquardt JU, Kloeckner R, Straub B.K., Bartsch F. Liver Resection for Intrahepatic Cholangiocarcinoma-Single-Center Experience with 286 Patients Undergoing Surgical Exploration over a Thirteen Year Period. J Clin Med. 2021 Aug 13;10(16):3559. doi: 10.3390/jcm10163559. PMID: 34441855; PMCID: PMC8396970.

• Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function. Cancers (Basel). 2021 Aug 5;13(16):3961. doi: 10.3390/cancers13163961. PMID: 34439116; PMCID: PMC8392843.

• Kaps L, Hildebrand K, Nagel M, Michel M, Kremer WM, Hilscher M, Galle PG, Schattenberg J.M., Wörns MA, Labenz C. Risk factors for poorer health literacy in patients with liver cirrhosis. PLoS One. 2021 Jul 27;16(7):e0255349. doi: 10.1371/journal.pone.0255349. PMID: 34314445; PMCID: PMC8315548.
   
• Gerber TS, Bartsch F, Wagner DC, Schindeldecker M, Heuft LK, Roth W, Lang H, Straub BK. Clinicopathological Significance of Syndecan-1 in Cholangiocarcinoma: A Study Based on Immunohistochemistry and Public Sequencing Data. J Clin Med. 2021 Jun 22;10(13):2745. doi: 10.3390/jcm10132745. PMID: 34206469; PMCID: PMC8269152.

• Gairing SJ, Thol F, Müller L, Hahn F, Thomaidis T, Czauderna C, Bartsch F, Pitton MB, Marquardt JU, Wörns MA, Galle PR, Moehler M, Weinmann A, Kloeckner R, Foerster F. The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma. J Clin Med. 2021 Jun 21;10(12):2732. doi: 10.3390/jcm10122732. PMID: 34205670; PMCID: PMC8235389.

• Gerber TS, Agaimy A, Hartmann A, Habekost M, Roth W, Stenzinger A, Schirmacher P, Straub BK. SWI/SNF-deficient undifferentiated/rhabdoid carcinoma of the gallbladder carrying a POLE mutation in a 30-year-old woman: a case report. Diagn Pathol. 2021 Jun 12;16(1):52. doi: 10.1186/s13000-021-01112-4. PMID: 34118935; PMCID: PMC8196506.

• Heinrich S, Seehofer D, Corvinus F, Tripke V, Huber T, Hüttl F, Penzkofer L, Mittler J, Abu Hilal M, Lang H. [Advantages and future perspectives of laparoscopic liver surgery] Chirurg. 2021 Jun;92(6):542-549. German. doi: 10.1007/s00104-020-01288-3. PMID: 32995902.

• Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score? Front Oncol. 2021 Jun 10;11:696183. doi: 10.3389/fonc.2021.696183. PMID: 34178694; PMCID: PMC8225326.

• Bartsch F, Heuft LK, Baumgart J, Hoppe-Lotichius M, Margies R, Gerber TS, Foerster F, Weinmann A, Straub BK, Mittler J, Heinrich S, Lang H. Influence of Lymphangio (L), Vascular (V), and Perineural (Pn) Invasion on Recurrence and Survival of Resected Intrahepatic Cholangiocarcinoma. J Clin Med. 2021 May 30;10(11):2426. doi: 10.3390/jcm10112426. PMID: 34070745; PMCID: PMC8199279.

• Müller L, Mähringer-Kunz A, Gairing SJ, Foerster F, Weinmann A, Bartsch F, Heuft LK, Baumgart J, Düber C, Hahn F, Kloeckner R. Survival Prediction in Intrahepatic Cholangiocarcinoma: A Proof of Concept Study Using Artificial Intelligence for Risk Assessment. J Clin Med. 2021 May 12;10(10):2071. doi: 10.3390/jcm10102071. PMID: 34066001; PMCID: PMC8150393.

• Müller L, Stoehr F, Mähringer-Kunz A, Hahn F, Weinmann A, Kloeckner R. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. J Hepatocell Carcinoma. 2021 May 13;8:403-419. doi: 10.2147/JHC.S285735. PMID: 34012930; PMCID: PMC8128497.

• Michel M, Kaps L, Maderer A, Galle P, Moehler M. The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy. Cancers (Basel). 2021 May 11;13(10):2296. doi: 10.3390/cancers13102296. PMID: 34064974; PMCID: PMC8150459.

• Kaps L, Ahlbrand CJ, Gadban R, Nagel M, Labenz C, Klimpke P, Hotz S, Boedecker S, Michel M, Kremer WM, Hilscher M, Galle PR, Kraus D, Schattenberg JM, Weinmann-Menke J. Applicability and safety of discontinuous ADVanced Organ Support (ADVOS) in the treatment of patients with acute-on-chronic liver failure (ACLF) outside of intensive care. PLoS One. 2021 Apr 1;16(4):e0249342. doi: 10.1371/journal.pone.0249342. PMID: 33793644; PMCID: PMC8016329.

• Penzkofer L, Huber T, Mittler J, Lang H, Heinrich S. Liver Resections Can Be Safely Performed in Cirrhotic Patients after Careful Patient Selection. Zentralbl Chir. 2021 Mar 4. German. doi: 10.1055/a-1373-6218. Epub ahead of print. PMID: 33663000.

• Jiang Y, Müller K, Khan MA, Assmann JC, Lampe J, Kilau K, Richter M, Kleint M, Ridder DA, Hübner N, Schmidt-Supprian M, Wenzel J, Schwaninger M Cerebral angiogenesis ameliorates pathological disorders in Nemo-deficient mice with small-vessel disease. J Cereb Blood Flow Metab. 2021 Feb;41(2):219-235. doi: 10.1177/0271678X20910522. Epub 2020 Mar 9. PMID: 32151223; PMCID: PMC8369998.

• Ridder DA, Schindeldecker M, Weinmann A, Berndt K, Urbansky L, Witzel HR, Heinrich S, Roth W, Straub BK. Key Enzymes in Pyrimidine Synthesis, CAD and CPS1, Predict Prognosis in Hepatocellular Carcinoma. Cancers (Basel). 2021 Feb 11;13(4):744. doi: 10.3390/cancers13040744. PMID: 33670206; PMCID: PMC7916936.

• Gairing SJ, Kloeckner R, Pitton MB, Baumgart J, von Auer-Wegener C, Lang H, Galle PR, Foerster F, Schattenberg JM. Multidisciplinary approach to the complex treatment for non-cirrhotic portal hypertension - case-report-based discussion. Z Gastroenterol. 2021 Jan;59(1):43-49. English. doi: 10.1055/a-1330-9827. Epub 2021 Jan 11. PMID: 33429449.
   

2020

• Wenzel J, Spyropoulos D, Assmann JC, Khan MA, Stölting I, Lembrich B, Kreißig S, Ridder DA, Isermann B, Schwaninger M. Endogenous THBD (Thrombomodulin) Mediates Angiogenesis in the Ischemic Brain-Brief Report. Arterioscler Thromb Vasc Biol. 2020 Dec;40(12):2837-2844. doi: 10.1161/ATVBAHA.120.315061. Epub 2020 Oct 8. PMID: 33028093.

• Michel M, Schattenberg JM. Liver-specific diagnostic for non-alcoholic fatty liver disease (NAFLD) - time to replace liver biopsy? Z Gastroenterol. 2020 Dec;58(12):1233-1240. German. doi: 10.1055/a-1291-8483. Epub 2020 Dec 8. PMID: 33291177.
   

2019

• Baumgart J, Jungmann F, Bartsch F, Kloth M, Mittler J, Heinrich S, Lang H. Two-Stage Hepatectomy and ALPPS for Advanced Bilateral Liver Metastases: a Tailored Approach Balancing Risk and Outcome. J Gastrointest Surg. 2019 Dec;23(12):2391-2400. doi: 10.1007/s11605-019-04145-9. Epub 2019 Feb 28. PMID: 30820795.

• Lang H, Baumgart J, Heinrich S, Tripke V, Passalaqua M, Maderer A, Galle PR, Roth W, Kloth M, Moehler M. Extended Molecular Profiling Improves Stratification and Prediction of Survival After Resection of Colorectal Liver Metastases. Ann Surg. 2019 Nov;270(5):799-805. doi: 10.1097/SLA.0000000000003527. PMID: 31634180.